Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD5K3 plus chemotherapy in acute lymphoblastic leukemia/lymphoblastic lymphoma (Ib/II dose-escalation and expansion)
CTR20253503Phase 2Active
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Oct 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pd5k3 in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), T-lymphoblastic lymphoma (T-LBL), precursor B-lymphoblastic lymphoma (B-LBL), sponsored by Chongqing Paijin Biotechnology. Started Oct 2025; status: active.
02
Drugs
pd5k3
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)T-lymphoblastic lymphoma (T-LBL)precursor B-lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on CTR20253503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253503.